The RePHyNe Registry is currently funded through support from two commercial partners, Beyond Air and Mallinckrodt Pharmaceuticals.
Our partners have provided unconditional support for this project and have no other operational or strategic involvement in the Registry. They will have no influence on Registry reports, presentations and publications, but their support will be recognised in all such material.
Commercial partnership is an interim arrangement allowing the Registry to be established and provide time for an application to be made for substantive funding from grant-giving bodies including charitable, academic and government institutions.
The Liverpool Women’s NHS Foundation Trust, UK, will act as the research sponsor for the RePHyNe Registry project.